Targeting Extra Domain A of Fibronectin to Improve Noninvasive Detection of Triple-Negative Breast Cancer
Journal of Nuclear Medicine · 2025
DOI: 10.2967/jnumed.124.268859 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nuclear Medicine, 2025. Verfasst von Justin S Hachey und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Weill Cornell Graduate School of Medical Sciences, New York, New York. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Fibronectins. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC) lags behind other breast cancer types in targeted therapeutic and diagnostic imaging agent development, largely due to high disease heterogeneity. Noninvasive imaging is essential for diagnosing and staging TNBC and predicting and measuring treatment response. This study targeted a conserved disease-specific extracellular matrix protein domain (the extra domain A of fibronectin [EDA-FN]), with a monoclonal antibody (F8) to overcome tumor cell marker heterogeneity and develop an imaging agent to detect multiple TNBC subtypes and improve diagnostic capacity. Methods: [89Zr]Zr-desferrioxamine [DFO]-F8 was synthesized and evaluated in vitro and in vivo for EDA-FN binding capacity to detect TNBC by PET/CT in several preclinical xenograft models. Results: [89Zr]Zr-DFO-F8 exhibited specific, blockable EDA-FN binding activity in vitro. In vivo experiments demonstrated high tumor uptake in preclinical TNBC xenograft models. [89Zr]Zr-DFO-F8 detected EDA-FN in subcutaneous and orthotopic TNBC xenografts and accumulated in aggressive disease concordantly with EDA-FN expression. Conclusion: EDA-FN imaging with [89Zr]Zr-DFO-F8 exhibits powerful tumor delineation in preclinical tumor delineation across TNBC molecular subtypes in vivo.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Weill Cornell Graduate School of Medical Sciences, New York, New York.
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
- Philochem AG, Otelfingen, Switzerland.
- Philogen S.p.A, Siena, Italy.
- Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology, Zurich, Switzerland; and.
- Department of Pharmacology, Weill Cornell Graduate School of Medical Sciences, New York, New York; lewisj2@mskcc.org.
Förderung
- NCI NIH HHS
Zitieren
APA
Hachey, J. S., Viray, T. D., Matasci, M., Ravazza, D., Neri, D., & Lewis, J. S. (2025). Targeting Extra Domain A of Fibronectin to Improve Noninvasive Detection of Triple-Negative Breast Cancer. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.124.268859
Vancouver
Hachey JS, Viray TD, Matasci M, Ravazza D, Neri D, Lewis JS. Targeting Extra Domain A of Fibronectin to Improve Noninvasive Detection of Triple-Negative Breast Cancer. Journal of Nuclear Medicine. 2025. doi:10.2967/jnumed.124.268859
BibTeX
@article{Hachey2025,
author = {Hachey, Justin S and Viray, Tara D and Matasci, Mattia and Ravazza, Domenico and Neri, Dario and Lewis, Jason S},
title = {Targeting Extra Domain A of Fibronectin to Improve Noninvasive Detection of Triple-Negative Breast Cancer},
journal = {Journal of Nuclear Medicine},
year = {2025},
doi = {10.2967/jnumed.124.268859}
}
EUVIMED